Advancements in Hematologic Malignancies: Innovations in Diagnosis and Therapy

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 827

Special Issue Editor


E-Mail Website
Guest Editor
Triservice General Hospital Taiwan/National Defense Medical Center, Taipei, Taiwan
Interests: hematologic malignancies; stem cell transplantation; immunotherapy; CAR-T cell therapy; multiple myeloma; leukemia and lymphoma; precision medicine; novel therapeutics; hematopoietic stem cells; drug resistance in cancer

Special Issue Information

Dear Colleagues,

We are pleased to announce the upcoming Special Issue on “Advancements in Hematologic Malignancies: Innovations in Diagnosis and Therapy” in Life. Hematologic malignancies, including leukemia, lymphoma, and multiple myeloma, remain significant challenges in medical research and clinical practice. However, recent innovations in molecular diagnostics, immunotherapy, and stem cell transplantation have provided new opportunities for improving patient outcomes. This Special Issue aims to highlight the latest advancements in the diagnosis, treatment, and management of hematologic cancers, including novel therapeutic approaches, precision medicine, and the use of emerging technologies such as CAR-T cell therapy. We welcome submissions from researchers and clinicians involved in the exploration of cutting-edge therapies, biomarkers for early detection, and strategies to overcome drug resistance in hematologic malignancies.

We would like to invite you to contribute your latest research findings and reviews to this Special Issue, which will serve as a platform to advance the knowledge and understanding of hematologic malignancies. We look forward to receiving your contributions.

Dr. Chohao Lee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hematologic malignancies
  • stem cell transplantation
  • CAR-T cell therapy
  • immunotherapy
  • multiple myeloma
  • leukemia
  • precision medicine
  • hematopoietic stem cells
  • drug resistance
  • novel therapeutics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 786 KiB  
Article
Optimizing Autologous Stem Cell Transplantation in Multiple Myeloma: The Significance of Pre-Transplant Controlling Nutritional Status Score
by Sıdıka Gülkan Özkan, Suna Avcı, Ali Kimiaei, Seyedehtina Safaei, Yüksel Altuntaş, Aslı Yüksel Öztürkmen, Zeynep Aslı Durak, Sinem Özdemir, Mohammad Adeeb Abbara, Tuğba Ağyol, Mehmet Serdar Yıldız and Hasan Atilla Özkan
Life 2025, 15(2), 289; https://doi.org/10.3390/life15020289 - 12 Feb 2025
Viewed by 616
Abstract
Nutritional status is an important prognostic factor in patients with multiple myeloma (MM). The Controlling Nutritional Status (CONUT) score has shown promise in predicting outcomes in various malignancies; however, its role in autologous stem cell transplantation (ASCT) in patients with MM remains unclear. [...] Read more.
Nutritional status is an important prognostic factor in patients with multiple myeloma (MM). The Controlling Nutritional Status (CONUT) score has shown promise in predicting outcomes in various malignancies; however, its role in autologous stem cell transplantation (ASCT) in patients with MM remains unclear. This study aimed to evaluate the significance of pre-transplant CONUT scores in predicting post-transplant engraftment kinetics and early complications in patients with MM undergoing ASCT. This single-center, retrospective study analyzed 59 multiple myeloma patients who underwent ASCT between 1 October 2022, and 1 July 2024. Pre-transplant CONUT scores were calculated, and their associations with various post-transplant outcomes were assessed using statistical analyses. Higher CONUT scores were independently associated with longer neutrophil engraftment times (p = 0.012). Patients who developed oral mucositis (OM) had significantly higher CONUT scores than those without OM (p = 0.028). A CONUT score cut-off of 2.5 demonstrated 100% sensitivity and 57.14% specificity in predicting OM (Area Under the Curve (AUC) 0.792, 95% CI: 0.654–0.930, p = 0.033). Our study demonstrates that a higher pre-transplant CONUT score is significantly associated with a delay in neutrophil engraftment and an increased risk of developing oral mucositis. These findings suggest that the CONUT score can serve as a valuable predictive tool for early post-transplant complications, thereby guiding targeted interventions and improving patient management. Full article
Show Figures

Figure 1

Back to TopTop